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ABSTRACT
Although elevated expression of neogenin-1 has been detected in human 
gastric cancer tissue, its role in gastric tumorigenesis remains unclear due to the 
lack of neogenin-1 studies in cancer. Therefore, we demonstrated here the function 
and regulatory mechanism of neogenin-1 in gastric cancer. Neogenin-1 ablation 
decreased proliferation and migration of gastric cancer cells, whereas its over-
expression reversed these effects. Xenografted analyses using gastric cancer cells 
displayed statistically significant inhibition of tumor growth by neogenin-1 depletion. 
Interestingly, galectin-3 interacted with HSF-1 directly, which facilitated nuclear-
localization and binding on neogenin-1 promoter to drive its transcription and gastric 
cancer cell motility. The galectin-3-increased gastric cancer cell motility was down-
regulated by HSF-1 depletion. Moreover, the parallel expression patterns of galectin-3 
and neogenin-1, as well as those of HSF-1 and neogenin-1, were detected in the 
malignant tissues of gastric cancer patients. Taken together, high-expression of 
neogenin-1 promotes gastric cancer proliferation and motility and its expression is 
regulated by HSF-1 and galectin-3 interaction. In addition, we propose further studies 
for neogenin-1 and its associated pathways to provide them as a proper target for 
gastric cancer therapy.
INTRODUCTION
Gastric cancer  is the second most common cause 
of cancer-related death  in the world [1]. Despite recent 
advances in treatments involving surgery, chemotherapy, 
and radiation therapy, gastric cancer is difficult to cure 
unless it is found at an early stage [2]. Even patients 
who present with the most favorable characteristics and 
who undergo curative surgical resection often die of 
recurrent disease due to metastasis and drug resistance [3]. 
Therefore, to cure gastric cancer, we need to understand 
the molecular mechanisms behind gastric cancer 
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metastasis and drug resistance. 
Through previous studies (GSE 29630), we reported 
microarray data on galectin-3 silencing in gastric cancer 
cell lines [4] which indicated that several cell motility-
related genes changed [5-8]. Among these changes, in 
the present study we focus on neogenin-1 expression. 
Neogenin-1 is a transmembrane receptor belonging to 
the immunoglobulin superfamily. It shares 50% amino-
acid identity with the human tumor suppressor molecule 
deleted in colon cancer (DCC) [9], and is a netrin receptor-
like DCC that binds repulsive guidance molecules (RGM); 
its functions as a RGM receptor have been studied [10-
11]. While DCC expression is restricted to the nervous 
system, neogenin-1, a cell adhesion molecule, is widely 
expressed in a variety of developing tissues, such as in 
the gastrointestinal tract of chickens, as well as on the 
surface of developing neurons in the heart, lungs, and 
pancreas [12]. Moreover, due to its similarity to DCC, 
neogenin-1 was thought to mediate axon guidance in a 
netrin-dependent manner. However, the knockout of the 
neogenin-1 gene in mice did not affect axon guidance 
phenotypes [13], and its DCC-independent functions 
have been determined, including the regulation of bone 
formation, mammary gland morphogenesis, and skeletal 
myofiber development [14-16]. 
Neogenin-1 seems to be involved in tissue growth 
regulation, cell to cell recognition, cellular transition 
from proliferation to terminal differentiation, and cell 
migration. Although neogenin-1 expression has been 
detected in many adult tissues, there is no information 
available regarding the status of neogenin-1 expression 
in the human ovary. Neogenin-1 is present in tissues 
where active growth takes place, and overexpression of 
neogenin-1 has been observed in a wide variety of human 
cancers including those of the breast, pancreas, cervix, 
colon, medulloblastoma and rectum [17-19]. Previous 
studies have also shown that neogenin-1 may promote 
cell migration and cell-cell adhesion in human vascular 
smooth muscle in addition to zebrafish neurectoderm 
[9, 20]. Also, neogenin-1 is involved in various aspects 
of cancer progression and metastasis [9]. It is expressed 
and has a role in colon cancer [21], breast cancer [22], 
pancreatic cancer [23], glioma [24], and esophageal 
squamous cell carcinoma (ESCC) [25]. Interestingly, 
its role and expression levels vary significantly among 
cancers affecting different organs. For example, low 
expression of neogenin-1 is seen in breast cancers, colon 
cancers and glioma, moderate expression in pancreatic 
cancer and high expression in ESCC compared to the same 
healthy organs. However, the role of neogenin-1 remains 
unclear because the opposite functions on cancer have 
been reported in several cancers [9, 22, 24].
In this study, we first determined the expression of 
neogenin-1 in gastric cancer patients and gastric cancer 
cells. The function of neogenin-1 was also determined 
by assessment of gain and loss of function of neogenin-1 
in gastric cancer cell proliferation and migration. 
Moreover, we also determined that neogenin-1 expression 
is regulated by transcriptional factor HSF-1, mediated 
stress response and the activity of specific heat shock 
proteins (HSPs) [26-28]. HSF-1 expression is elevated 
in various cancers, including human prostate carcinoma 
cell lines, and has been shown to support proliferation 
of several cancer cell lines [27-31]. Finally, we assessed 
how galectin-3 regulates the expression of neogenin-1, 
specifically through interaction with HSF-1. Therefore, 
we demonstrate herein the effects of neogenin-1 on 
gastric cancer cell proliferation and migration, as well as 
the regulation of its expression by HSF-1 and galectin-3 
interactions. 
RESULTS 
Detection of expression level of neogenin-1 in 
tissues of gastric cancer patients
We investigated the expression of neogenin-1 in 59 
cases of gastric cancer tissues and normal tissues of gastric 
cancer patients (Fig. 1). The expression of neogenin-1 
was detected in normal tissues, especially in cytoplasm 
of glandular cells (Fig. 1A). Although the case number of 
patients was not enough, we found the expression levels 
of neogenin-1 was higher in diffuse type than intestinal 
type of gastric cancer tissues (Fig. 1B-C). Interestingly, 
neogenin-1 was highly detected in signet ring cell 
carcinoma of diffuse type gastric cancer tissues (Fig. 1D-
E), which has a metastatic property on the various cancer 
Figure 1: Immunohistochemical analysis of neogenin-1 
expression in human gastric cancer patient tissues. 
The evaluation of neogenin-1 expression investigated in 
gastric cancers. (A) Adjacent normal tissues of gastric cancer, 
(B) Intestinal type adenocarcinoma gastric cancer tissue, (C) 
Diffuse type adenocarcinoma gastric cancer tissue, (D and E) 
signet ring cell carcinoma gastric cancer, on tissue microarrays 
by immunohistochemical method. Neogenin-1 (brown) is 
mostly expressed in cytoplasms of each tissue through staining 
intensities. (A-D) panels magnification, x 200, (E) panel 
magnification, x400
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types [32-34]. 
Effect of the ablation of neogenin-1 or netrin-1 on 
gastric cancer cell proliferation and migration
Whereas neogenin-1 expression was highly detected 
in 10 of 12 gastric cancer cell lines, both ligand of 
neogenin-1, netrin-1 and RGMa were low expressed or 
unexpressed in most gastric cancer cell lines, respectively 
(Suppl. Fig. 1). We depleted the expression of neogenin-1 
and netrin-1 by each siRNA to determine the effect on 
cell proliferation in six gastric cancer cell lines (Suppl. 
Fig. 2 and Fig. 2A). The cell proliferation was reduced 
by the ablation of neogenin-1, and the strongest reduction 
was detected in AGS cells and YCC-2 cells. However, the 
ablation of netrin-1 did not show any visible reduction 
of proliferation in six gastric cancer cell lines. The cell 
migration by ablation of neogenin-1 distinctively lessened 
the migration of 5 of the gastric cancer cells except SNU-
216, whereas the ablation of netrin-1 had no significant 
reduction (Fig. 2B). Our results suppose that the effect 
of neogenin-1 on the proliferation and migration gastric 
cancer cells and is independent of its ligand netrin-1. 
Effect of ablation of neogenin-1 in vivo in gastric 
cancer cell xenografted mice
We prepared two clones of neogenin-1 shRNA 
stable expressing AGS cells and inoculated in nude mice 
(Fig. 2C-D). Compared to tumors growth made from 
negative control LacZ shRNA expressing AGS cells, the 
neogenin-1 ablation by both shRNAs showed reduced 
Figure 2: Effect of each ablation of neogenin-1 or netrin-1 on the proliferation and migration of six gastric cancer cells 
and on AGS xenografted mice (A) Cell proliferation was checked in 6 gastric cancer cell lines (AGS, MKN-28, YCC-2, 
SNU-216, SNU-601, and SNU-668) after transfection with scRNAs, neogenin-1 siRNA or netrin-1 siRNA (* p<0.001). (B) 
Six gastric cancer cell lines were transfected with scRNAs, neogenin-1 siRNA or netrin-1 siRNA, and analyzed by migration and invasion 
assays, with the results presented as histograms (* p<0.04). All experiments were performed in triplicate. (C) The effect of neogenin-1 on 
tumor growth of xenografts in nude mice. 50ul of AGS SQ cells (1 x 106) with Matrigel were implanted into Balb/c-nude mice to form 
subcutaneous xenografts. Tumor volumes were measured at different time points and are presented in photographs taken at day 28 and in 
a graph (D). Data are presented as the mean and standard error of the mean (SEM). Unpaired student’s t-test was used for the comparison 
between the two groups (*, ** p<0.002).
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tumor growth in xenografted mice. These data strongly 
suggest that neogenin-1 accelerates in vivo gastric cancer 
progression.
Transient transfection of neogenin-1 accelerated 
the proliferation, migration and invasion of SNU-
668 gastric cancer cells
Neogenin-1 over-expression plasmids were 
transfected into SNU-668 cells, which demonstrate low 
expression of neogenin-1 in twelve gastric cancer cell lines 
(Fig. 3A-C). In all cases, cell proliferation, migration and 
invasion were increased by neogenin-1 over-expression. 
Previously, it was reported that neogenin-1 regulates 
Rho/Rac/ROCK1 activity [35]. We reduced neogenin-1 
expression, and then detected an associated decrease in 
both phosphorylated ROCK1 and total ROCK1 protein 
levels in AGS cells (Suppl. Fig. 3A). The depletion of 
ROCK1 also reduced AGS cell migration and invasion 
(Suppl. Fig. 3B). To establish whether neogenin-1 
induced gastric cancer cell migration and invasion through 
ROCK1 activation, we over-expressed neogenin-1 in 
SNU-668 cells and decreased the expression of ROCK1 
by ROCK1 siRNA. Then, cell migration and invasion 
assays were performed using these cells (Fig. 3D-E). 
As shown in Figure 3E, over-expression of neogenin-1 
increased cell migration and invasion, whereas ROCK1 
depletion reversed these effects. Moreover, the reduction 
in phosphorylation of ROCK1 was also detected in in vivo 
neogenin-1-depleted tumors of AGS cell-xenografted mice 
(Suppl. Fig. 4). Taken together, neogenin-1 appears to 
regulate ROCK1 activation leading to gastric cancer cell 
migration and invasion. 
Figure 3: Effect of transient transfection of neogenin-1 in SNU-668 gastric cancer cells on the proliferation, migration 
and invasion. (A-C) SNU-668 cells were transfected with pcDNA3.0 control vector and pcDNA3.0-neogenin-1 expression vector for 
48 h. (A) Western blot analysis of neogenin-1 protein expression and crystal violet staining of cells, (B) Cell proliferation measured by 
WST assay (* p<0.001), (C) Cell migration assay and cell invasion assay (* p<0.0001), were performed as described in the methods. (D) 
Expression levels of neogenin-1 and ROCK1-1 were detected by RT-PCR and Western blot analysis in SNU-668 cells, which were infected 
with lentivirus-containing LacZ or neogenin-1 full-length, and then were transfected with scRNA or ROCK1 siRNA. β-actin was used as a 
loading control. (E) The cells were analyzed with cell migration and invasion assays, and data are presented as histograms (*, ** p<0.001). 
All experiments were performed in triplicate.
Oncotarget3390www.impactjournals.com/oncotarget
Ablation of galectin-3 and neogenin-1 inhibits 
AGS gastric cancer cell migration and invasion 
In our previous microarray study, we found 
galectin-3 regulates neogenin-1 expression (GSE 29630), 
so we focus on the galectin-3 and neogenin-1 relationship. 
The expression levels of galectin-3 and neogenin-1 were 
checked in 12 gastric cancer cell lines (Suppl. Fig. 1), 
and AGS (high expression of galectin-3) and SUN-638 
(without expression of galectin-3) were selected for 
the following experiments. First, we transfected AGS 
cells with galectin-3 siRNA or neogenin-1 siRNA, and 
detected the expressions of galectin-3 and neogenin-1 
using RT-PCR and Western blotting, respectively (Fig. 
4A). Ablation of galectin-3 could reduce the expression 
of neogenin-1, but neogenin-1 had no effect on galectin-3 
expression. After we over-expressed galectin-3 in 
SNU-638 cells, we detected an increase in neogenin-1 
expression (Fig. 4B). Taken together, these results 
suggest that galectin-3 regulates neogenin-1 expression. 
To determine the effect of neogenin-1 on cell migration 
and invasion, we performed cell migration and invasion 
assays after treatment with each siRNA of galectin-3 and 
neogenin-1 in AGS cells (Fig. 4C-D). The galectin-3 or 
neogenin-1-depleted cells were no longer mobile, and 
the total number of migrated cells and invasive cells was 
reduced by almost half.
Galectin-3 promotes motility of human gastric 
cancer cells through up-regulation of neogenin-1 
expression
We also examined whether galectin-3 regulates cell 
motility and invasion through neogenin-1 expression. 
Galectin-3 overexpressing cells by a galectin-3-
containing lentivirus construct showed an increased level 
of neogenin-1 protein, and we abolished this increase 
using neogenin-1 siRNA (Suppl. Fig. 5A). Interestingly, 
Figure 4: Effect of galectin-3 depletion on the expression of neogenin-1 in human gastric cancer cells (A) mRNA 
and protein levels of galectin-3 and neogenin-1 after transfection of AGS cells with scrambled siRNA (scRNA), galectin-3 
siRNA, or neogenin-1 siRNA. β-actin was used as a loading control. (B) Expression levels of galectin-3 and neogenin-1 in SNU-
638 cells as determined by western blotting after transfection with pcDNA3.1/NT-GFP-galectin-3 and vector control of pcDNA3.1/NT-
GFP. (C-D) After transfection of AGS cells with scrambled siRNA (scRNA), galectin-3 siRNA, or neogenin-1 siRNA, the migration and 
invasion assay were performed as described in “Methods” and quantification of (C) cell migration (*, ** p<0.0001) and (D) cell invasion 
are presented as a histogram (*, ** p<0.0001). All experiments were performed in triplicate.
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galectin-3 over-expression also induced phosphorylation 
of ROCK1, whereas ablation of neogenin-1 reduced its 
phosphorylation (Suppl. Fig. 6A). Cell migration and 
invasion assays were also performed on these cells. 
Galectin-3 overexpression increased cell migration and 
invasion, while neogenin-1 silencing significantly reduced 
the increases caused by galectin-3 overexpression (Suppl. 
Fig. 5B). These results suggest that galectin-3 promotes 
gastric cancer cell motility by increasing neogenin-1 
expression.
Transcriptional regulation of neogenin-1 by 
galectin-3 through interaction with HSF-1 
transcriptional factor
In order to further explore how galectin-3 increases 
neogenin-1 expression in gastric cancer cells, we focused 
on the transcription factor, heat shock factor 1 (HSF-1), 
as a major regulator of heat shock protein transcription. 
We analyzed the binding site of HSF-1 in the neogenin-1 
promoter (Fig. 5A), and examined the DNA binding 
activity of HSF-1 with or without galectin-3 by ChIP assay 
(Fig. 5B). In the presence of galectin-3, HSF-1 bound to 
the promoter regions of neogenin-1, but not in the absence 
of galectin-3. A HSF-1 luciferase assay was also performed 
to detect transcriptional activity of HSF-1 with or without 
galectin-3 expression (Fig. 5C). Transcriptional activity 
of HSF-1 was decreased in the absence of galectin-3. 
Therefore, we carried out an immunoprecipitation assay, 
and observed a strong interaction between galectin-3 and 
HSF-1 (Fig. 5D). Interestingly, the localization of HSF-
1 was changed by galectin-3 (Fig. 5E). We separated the 
cytosol and nuclear fractions of cell lysates treated with 
galectin-3 siRNA or HSF-1 siRNA. In the absence of 
galectin-3, most HSF-1 expression was detected in the 
cytosol, suggesting less transcriptional activity. However, 
the absence of HSF-1 had no effect on the galectin-3 
localization. These results suggest that galectin-3 
contributes to the binding of the neogenin-1 promoter 
by interacting with HSF-1 protein, thereby increasing 
Figure 5: Transcriptional regulation of neogenin-1 through interaction with galectin-3 and HSF-1 transcriptional 
factor. (A) The proximal HSF-1 binding site is located between -1478 and -1470 from the initiation codon of NEO1 gene. (B) Chromatin 
immunoprecipitation assay was performed as described in “Methods.” Total genomic DNA was used in the input lane as a control for the 
PCR assay. (C) Luciferase activity of HSF-1 in AGS cells treated with galectin-3 siRNA or HSF-1 siRNA. A luciferase assay was performed 
using a HSF-1 binding site luciferase vector transfection with galectin-3 siRNA or HSF-1 siRNA (*, ** p<0.001). The experiments were 
performed in triplicate. (D) The detection of the interaction between galectin-3 and HSF-1 by immunoprecipitation was performed as 
described in “Methods,” and then galectin-3 and HSF-1 were detected by western blot analysis. Whole-cell lysate (WCL) was used as a 
loading control. (E) Protein levels of galectin-3 and HSF-1 were detected in the nuclear and cytosol fractions of AGS cells which were 
transfected with galectin-3 or HSF-1 siRNA. Lamin A/C was used as a control for the nuclear fraction.
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neogenin-1 expression by transcriptional regulation.
HSF-1 promotes motility of human gastric 
cancer cells through up-regulation of neogenin-1 
expression
Because HSF-1 increased neogenin-1 expression, 
we determined the regulatory effect of HSF-1 on migration 
of gastric cancer cells (Fig. 6). First, we examined the 
decreased expression of both neogenin-1 and HSP70 
[36], a downstream target of HSF-1, after the depletion 
of HSF-1 or galectin-3 (Fig. 6A). The ablation of HSF-
1 reduced the gastric cancer cell migration significantly 
(Fig. 6B). Moreover, increased expression of neogenin-1 
by galectin-3 over-expression was reduced in the absence 
of HSF-1. HSP70 expression was also increased by 
galectin-3 over-expression, and was diminished in the 
absence of HSF-1 (Fig. 6C). The increased cell migration 
and invasion by galectin-3 overexpression decreased with 
HSF-1 depletion (Fig. 6D). Taken together, our results 
demonstrated that HSF-1 increases gastric cancer cell 
motility through regulation of neogenin-1 expression, and 
the transcriptional activation of HSF-1 is regulated by 
galectin-3.
Correlation between neogenin-1 and galectin-3 
expression in malignant and normal tissues from 
gastric cancer patients 
The expression levels of galectin-3 and neogenin-1 
were analyzed in 20 gastric cancer patients obtained from 
the National Cancer Center of Korea. Total RNA of normal 
and cancer tissues from these patients were prepared and 
RT-PCR was performed (Suppl. Fig. 6). We quantified 
galectin-3 and neogenin-1 expression using ImageJ 
and created a graph (Fig. 7A). The expression levels of 
Figure 6: Effect of HSF-1 depletion on the expression of neogenin-1 and gastric cancer cell motility (A) Detection 
of mRNA and protein levels of galectin-3, HSF-1, HSP70, and neogenin-1 after transfection of AGS cells with scRNA, 
galectin-3 siRNA and HSF-1 siRNA. β-actin was used as a loading control. (B) After transfection of AGS cells with scrambled siRNA 
(scRNA), or HSF-1 siRNA, the migration assay were performed and quantification of cell migration was presented as a histogram (*, ** 
p<0.001). (C) Expression levels of galectin-3, HSF-1, HSP70 and neogenin-1 were detected by RT-PCR and Western blotting analysis in 
SNU-638 cells, which were infected with lentivirus-containing LacZ or galectin-3 full-length, and then followed by transfection with HSF-
1 siRNA or scRNA. β-actin was used as a loading control. (D) The cells were analyzed by migration assay and invasion assay, and data are 
presented as histograms (*, ** p<0.001). All experiments were performed in triplicate.
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both galectin-3 and neogenin-1 were higher in cancer 
tissues than in normal tissues. Furthermore, analysis of 
20 primary human gastric tumors revealed an overall 
positive correlation between increased active expression 
of galectin-3 and elevated neogenin-1 expression, except 
in 6 tissues (Fig. 7B). We could not determine clinical 
implications from these samples, maybe due to the small 
number of samples. However, these results revealed a 
significant positive correlation between the expression 
levels of galectin-3 and neogenin-1 in gastric cancer 
patient tissues.
Moreover, we also established the parallel protein 
expression and co-localization of HSF-1 and neogenin-1 
in malignant tissues of gastric cancer patients (Fig. 7C). 
Therefore, our results strongly suggest that neogenin-1 
was more detected in malignant tissues and its expression 
was positively correlated with both HSF-1 and galectin-3 
in the malignant tissues of gastric cancer patients.
DISCUSSION
In this study, we confirmed for the first time that 
neogenin-1 is highly expressed in gastric cancer and 
promotes gastric cancer proliferation and migration. It is 
unclear why neogenin-1 is differentially expressed across 
organs. For example, the loss of expression of neogenin-1 
in breast cancer and colorectal cancer has already been 
studied, and it appears that the RGMa/neogenin-1 
interaction inhibits cancer growth and migration [21-22]. 
In our study, the expression of neogenin-1 was relatively 
high and easily detectable in twelve gastric cancer cell 
lines. In human tissues of gastric cancer patients, the 
expression level was highly detected in malignant tissues 
than normal counterparts, especially in diffuse type of 
Figure 7: Positive association between galectin-3 and neogenin-1 expression, and HSF-1 and neogein1 expression in 
malignant and normal tissues from gastric cancer patients (A) mRNA expression levels of galectin-3 and neogenin-1 from 
malignant tissues of 20 gastric cancer patients are presented in a histogram. (B) Expression levels of galectin-3 and neogenin-1 
were calculated using ImageJ in normal and tumor tissues of 20 gastric cancer patients. Those p values were calculated using student T-test. 
(C) Protein expression of HSF-1 and neogenin-1 in the malignant tissues of gastric cancer patients were shown by immunohistochemical 
staining (brown) with hematoxylin and eosin (H&E) and detected by inverted light microscope. Magnification; X200 (up) and X400 
(down). 
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signet ring cell carcinomas. It may provide the cue that 
neogenin-1 is involved in motility of gastric cancer 
cells, because signet ring cell carcinoma has a metastatic 
property on the various cancer types [32-34]. Neogenin-1 
ligands netrin-1 and RGMa were expressed at low levels 
or not at all in gastric cancer cells, respectively. Moreover, 
only ablation of neogenin-1 reduced gastric cancer cell 
proliferation and migration, whereas ablation of netrin-1 
had little effect. Neogenin-1 is thought to be up-regulated 
during gastric cancer development and is involved 
in gastric cancer growth and metastasis in a ligand-
independent manner. In contrast to DCC, neogenin-1 
appears to have varying expression and function 
depending on the organ from which the cancer originated 
[9]. We suggest that alternatively spliced isoforms of 
neogenin-1 are expressed in various developmental tissues 
and development stages, and that these isoforms may 
function differently. However, the regulatory mechanisms 
for these spliced isoforms remain to be determined. 
Moreover, detailed analyses of the expression and function 
of DCC and neogenin-1 are also needed at the single-cell 
level as well as in different organs. 
To understand how neogenin-1 expression is up-
regulated in gastric cancer, we searched for transcription 
factor binding sites in the neogenin-1 promoter region 
using a transcription factor binding site prediction 
program. Next, we verified that the HSF-1 transcriptional 
factor interacts with the neogenin-1 promoter. Many 
cancers histologically exhibit activated HSF-1 and 
increased HSP levels, and activate oncogenes to regulate 
cell proliferation and cell motility [37-38]. Another 
study also demonstrated that HSF-1 plays an essential 
role in the development of lymphoma in p53-deficient 
mice, and of carcinomas in the Ras tumor model [28, 
39]. Whether the multifaceted HSF-1-mediated stress 
response plays a causal, supportive, or inhibitory role in 
mammalian oncogenesis remains unclear. Interestingly, 
we first demonstrated that HSF-1 activation is induced 
by galectin-3 interaction. Usually HSF-1 is activated 
by extracellular stresses, e.g., heat shock, cytokines 
or ROS [40]. Over-expression of galectin-3 facilitated 
the nuclear-localization of HSF-1 and binding to the 
promoter of neogenin-1. Related to this, HSF-1-mediated 
cell motility was caused by an increase in neogenin-1. 
Moreover, parallel and high expression of neogenin-1 and 
galectin-3, as well as neogenin-1 and HSF-1, was detected 
in human gastric cancer tissue. These data strongly 
suggest that over-expression of HSF-1 and galectin-3 
jointly increases neogenin-1 expression both in vivo 
and in vitro. Neogenin-1 also appears to regulate gastric 
cancer cell motility through the activation of ROCK 
[35]. The function of ROCK1 is cell type-specific and 
remains controversial. However, there are several studies 
demonstrating that up-regulation of ROCK signaling 
contribute to cancer progression and metastatic behavior 
[41-42]. Moreover, ROCK1 increases gastric cancer cell 
migration and invasion [43], and the inhibition of ROCK1 
induces apoptosis in gastric cancer cells [44], suggesting 
that neogenin-1 increases the activation of ROCK1 and, 
in turn, promotes gastric cancer cell survival and motility. 
Taken together, our results suggest that neogenin-1 
increases gastric cancer cell motility, and its expression 
is highly regulated in gastric cancers through interactions 
with galectin-3 and HSF-1. Further study will be critical 
in determining the role and regulation of neogenin-1 in 
various cancer types, as well as the roles of neogenin-1, 
galectin-3 and HSF-1 regulation in cancer metastasis.
METHODS
Cell culture 
12 human gastric cancer cell lines (AGS, MKN28, 
YCC-2, KATOIII, SNU-1, SNU-5, SNU-16, SNU-216, 
SNU-601, SNU-638, SNU-668, and SNU-719) obtained 
from Korea Cell Line Bank were cultured in DMEM or 
RPMI 1640 medium supplemented with 5% fetal bovine 
serum (FBS) and 1% Antibiotics as described previously 
[45]. The KCLB authenticate the phenotypes of these cell 
lines. 
siRNA transfection
Galectin-3, neogenin-1, netrin-1, and HSF-1 
siRNA transfections were performed with Lipofectamine 
RNAiMAX reagent (Invitrogen, USA) following 
the manufacturer’s instructions. The coding strand 
of human galectin-3 siRNAs was 5’-AUAUGAAG 
CACUG GUGAGGUCUAUG-3’ and that of human 
neogenin-1 siRNA was 5’-AGAUCUGGAGGUU 
UCACAUCUUUGG-3’, and each was purchased 
from Invitrogen. Human netrin-1 siRNA was 
5’-GGGUGCCCUUCCAGUUCTA-3’ and human HSF-1 
siRNA was 5’-GCGGCAGC UCAACAUGUAU-3’, and 
each was purchased from Genolution (Korea).
RNA isolation and reverse transcription-
polymerase chain reaction (RT-PCR)
Total RNA was extracted from human gastric 
cancer cells and gastric cancer patient tissues with 
TRIzol reagent (Invitrogen, USA) according to the 
manufacturer’s protocol. RT was carried out using a 
RT system (Promega, USA), and PCR was performed 
with Ex-taq DNA polymerase (TaKaRa, Japan). The 
sequences of primers were as follows: Galectin-3: 
5’-CAGTGCTCCTGGAGGCTATC-3’ (sense) and 
5’-AAGGGGAAGGCTGACTGTCT-3’ (anti-sense); 
NEO1: 5’- AGGAGAGATGCAAGTAACCA -3’ 
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(sense) and 5’-GTTTCCCACGTAACAGTGAT-3’ 
(anti-sense); NTN-1 (Netrin-1); 5’- 
TGCAAGTGTCCCAAAATCAA-3’ (sense) and 
5’-GCACTTGCCCTTCTTCTCAC-3’ (anti-sense); 
HSP70; 5’- AGAGCCGA GCCGACAGAG -3’ (sense) 
and 5’-CACCTTGCCGTGTTGGAA-3’ (anti-sense) 
β-actin: 5’-AGCCTCGCCTTTGCCGA-3’ (sense) and 
5’-CTGGTGCCTGGGGCG-3’ (anti-sense). 
Fractionation of cellular extracts and Western 
blot analysis
Nuclear or cytoplasmic extracts were prepared 
from AGS cells after galectin-3 siRNA and HSF-1 siRNA 
treatments. These experiments have been described in a 
previous study [46]. Western blot analysis was carried 
out using the methodology from a previous study [47]. 
Briefly, cells were lysed in RIPA buffer (Biosesang, 
Korea) containing a protease inhibitor cocktail (Sigma, 
USA). The primary antibodies were: anti-β-actin, anti-
galectin-3, anti-neogenin-1, anti-HSF-1, and anti-HSP70 
from Santa Cruz, and anti-ROCK-1 from Cell Signaling, 
also, anti-pROCK-1(T455/S456) antibody from Bioss. 
Proteins of interest were detected using ECL solutions 
(Amersham Life Science) with an LAS-3000 (Fujifilm) 
detector according to the manufacturer’s directions.
Immunoprecipitation assays
Cell lysates containing 750 μg proteins was pre-
cleared by incubation with 40 μl protein-A/G linked 
agarose beads (Santa Cruz, CA, USA) for 1 hour at 4oC. 
After the beads were spun down, the supernatant was 
incubated with 1 μg its specific antibody (anti-galectin-3 
and anti-HSF-1) overnight at 4oC, followed by incubation 
with 40 μl protein-A/G agarose beads for 1 hour. Mouse 
IgG (Santa Cruz, CA, USA) was used as the negative 
control. After the incubation, beads were washed three 
times in a RIPA buffer before being dissolved in a SDS-
PAGE loading buffer. Western blot analysis was performed 
as described above. 
Transfilter migration and invasion assays 
Briefly, AGS, MKN-28, YCC-2, SNU-216, SNU-
601, SNU-668 and SNU-638 cells were transfected with 
galectin-3, neogenin-1, netrin-1, and ROCK1 siRNAs. 
One day after the transfection, cells (AGS-1x104, MKN-
28-1x104, YCC-2-1x104, SNU-216-1x104, SNU-601-
1x104, SNU-668-1x104 and SNU638-1x104 each well) 
were isolated and added to upper Transwell (Corning 
Costar, USA) chambers with 0.5 mg/ml collagen type 
I (BD bioscience, Korea)-coated filters for migration 
assay, and with 1/15 dilution of Matrigel (BD bioscience, 
Korea)-coated filters for invasion assays. RPMI 1640 
containing 10% FBS and 1% antibiotics was added to the 
lower chamber and incubation was continued for 20 hours. 
Cells that migrated or invaded to the lower chamber were 
quantified after H&E staining. For quantification, cells 
were counted at 5 randomly selected areas in each well 
using wide-field microscopy. Data were expressed as mean 
± SD from three independent experiments. 
Galectin-3 over-expression construction and 
infection 
The galectin-3 overexpression vector (pcDNA3.1/
NT-GFP-galectin-3) and lentiviral vectors containing 
galectin-3 over-expression were constructed by inserting 
the galectin-3 gene into the lentiviral vector pLL3.7, 
as described in a previous study [48]. The plasmid 
pcDNA3.0–neogenin-1 kindly provided by Dr. Patrick 
Mehlen (Universite´ de Lyon), was transiently transfected 
into cells using Lipofectamine 2000 reagent (Invitrogen) 
according to the manufacturer’s instructions.
Crystal violet staining. 
Cells were transfected with 4ug of pcDNA3.0 
Eempty vector and pcDNA3.0-Neogenin-1 full length by 
reverse transfection method using Lipofectamine 2000. 
For crystal violet staining, cells were plated into 6 well 
culture dishes and stained with crystal violet 2 days after 
transfection [49].
Cell proliferation analysis. 
Inhibition of cell proliferation by netrin-1, 
neogenin-1 siRNA treatment was measured by WST 
assay. The AGS, MKN-28, YCC-2, SNU-216, SNU601 
and SNU668 cells were plated in 96-well culture plates 
(3 × 103 per well). After incubation for 24 h, the cells 
were treated with 20nM of netrin-1, neogenin-1 siRNA 
treatment for 48 hr. WST solution (Daeil, korea) was 
subsequently added to each well. After 1-3h of additional 
incubation, the plate was shaken gently. The absorbance 
was measured on an ELISA reader at a test wavelength 
of 450 nm. 
Chromatin immunoprecipitation assay
We performed a chromatin immunoprecipitation 
(ChIP) assay using a ChIP assay kit (Upstate). 
Samples were applied to dishes after galectin-3 siRNA 
treatment and assays were conducted following the 
manufacturer’s instructions. Anti-galectin-3, and anti-
HSF-1 and normal mouse/rabbit IgG were used to 
immunoprecipitate DNA-containing complexes. Prior to 
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PCR, primers were prepared for HSF-1 with neogenin-1 
promoter binding sites, neogenin-1 promoter (-2474) 
5’-CCTAGAGCAGGTGGCTTCTG-3’ and (-2274) 5’- 
GAATCCCAGTG TCCGAGGT-3’. PCR was performed 
with Ex taq (Takara).
Luciferase activity of HSF-1 promoter
For HSF-1 reporter assays, a HSF-1 binding site 
luciferase construct (pGL3-HSE, containing 3 copies of 
HSE third pentamer consensus sequence reporter plasmid 
[50] was used. Gastric cancer cells were transfected with 
pGL3-HSE and a β-gal control construct, and HSF-1 
promoter activities were analyzed by luciferase gene 
activity as described previously [51]. 
Preparation of Neogenin-1-depleted AGS gastric 
cancer cell xenografted mice
All animal experiments were approved by the 
Institutional Review Board of the National Cancer Center 
(NCC Korea) and performed in specific pathogen-free 
facilities and under conditions in accordance with the 
Guidelines for the Care and Use of Laboratory Animals 
of NCC (NCC-11-034D). The preparation of xenografted 
mice has been described in a previous study [52].
Fractionation of cellular extracts
Nuclear or cytoplasmic extracts were prepared 
from AGS cells after galectin-3 siRNA and HSF-1 siRNA 
treatments. These experiments have been described in a 
previous study [5].
Human gastric cancer tissue micro-array analyses 
and Preparation of frozen tissues from gastric 
cancer patients
Core tissue biopsy specimens (2-mm diameter) 
were obtained from individual paraffin-embedded gastric 
carcinomas (donor blocks) and arranged in new recipient 
paraffin blocks (tissue array blocks) using a trephine 
apparatus (Superbiochips Laboratories, Seoul, Korea). 
Immunohistochemical analysis of HSF-1 and Neogeinin1 
was performed as described previously [53]. Two pairs 
of 2-mm-sized biopsy specimens were obtained from 20 
patients with gastric adenocarcinoma during diagnostic 
endoscopic submucosal dissection. Immediately after 
biopsy, these tissue samples were frozen in liquid nitrogen 
in a deep freezer at -70℃ until experimental use. All 
participants provided written informed consent. All 
experiments were approved by the Institutional Review 
Board of the National Cancer Center as approval number 
NCCNSH 03-024. 
Statistics analysis
All data were obtained from at least three 
independent experiments and are presented as mean ± 
SD, unless otherwise indicated. Statistical analysis was 
performed using one-way ANOVA and student T-test 
methods. Data were considered significant if p<0.05.
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